Shree Ganesh Remedies Ltd

Shree Ganesh Rem Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Shree Ganesh Remedies Ltd

₹ 850 4.22%
03 Jul 4:01 p.m.
ganeshremedies.com BSE: 540737
About

Shree Ganesh Remedies is engaged in the business of Pharma Intermediate.

Key Points

Business segments[1]
Pharmaceutical intermediates: 32+ products; 54 Cr sales in FY23 (vs 51 Cr in FY22)
Human pharma segments: Antipsychotic, Antidepression, Oncology, Diabetic, Diuretic
Veterinary segment: Feed Additives, Antiparasitic, Anti-Inflammator
Fine and Specialty Chemicals: 11+ products; 37 Cr. sales in FY23 (vs 20 Cr. in FY22)
Industries served: Aroma & Health, Agrochem, Polymer, Electronics

Website BSE
  • Market Cap ₹ 1,091 Cr.
  • Current Price ₹ 850
  • High / Low ₹ 935 / 380
  • Stock P/E 38.8
  • Book Value ₹ 95.4
  • Dividend Yield 0.06 %
  • ROCE 27.6 %
  • ROE 26.6 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is expected to give good quarter
  • Company has delivered good profit growth of 35.1% CAGR over last 5 years
  • Debtor days have improved from 88.7 to 58.9 days.
  • Company's median sales growth is 27.3% of last 10 years

Cons

  • Stock is trading at 8.91 times its book value
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
15 13 17 21 21 18 21 22 30 27 33 28 37
10 10 13 15 16 13 16 17 21 20 24 20 20
Operating Profit 5 3 4 6 5 4 5 5 9 7 9 8 17
OPM % 33% 24% 26% 27% 23% 24% 25% 24% 29% 25% 28% 30% 45%
0 1 0 1 1 1 1 1 0 1 1 1 1
Interest 0 0 0 0 0 0 -0 0 0 0 0 0 0
Depreciation 1 1 1 1 1 1 1 1 1 1 1 2 2
Profit before tax 4 3 4 6 5 4 5 6 8 6 9 7 16
Tax % 25% 29% 23% 25% 26% 26% 26% 24% 15% 27% 24% 37% 22%
3 2 3 4 4 3 4 4 7 5 7 4 13
EPS in Rs 2.37 1.83 2.36 3.28 3.00 2.24 3.08 3.40 5.23 3.71 5.12 3.46 9.84
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
13 18 16 16 20 27 35 58 49 71 90 126
10 14 14 14 16 22 26 47 35 53 67 84
Operating Profit 2 5 2 2 4 5 9 11 14 18 23 42
OPM % 19% 25% 13% 12% 21% 19% 25% 19% 28% 25% 26% 33%
1 1 0 0 0 2 1 4 2 4 3 3
Interest 0 0 0 0 0 0 0 0 0 0 0 1
Depreciation 1 1 1 1 1 1 1 2 3 3 4 6
Profit before tax 2 5 2 2 4 6 9 13 13 18 23 38
Tax % 33% 32% 33% 34% 33% 28% 28% 24% 25% 26% 25% 26%
1 3 1 1 3 5 6 10 10 13 17 28
EPS in Rs 9.25 20.06 7.94 6.75 16.50 3.66 4.88 7.52 7.62 10.47 13.30 21.97
Dividend Payout % 0% 0% 0% 0% 0% 19% 18% 14% 18% 4% 2% 0%
Compounded Sales Growth
10 Years: 21%
5 Years: 29%
3 Years: 37%
TTM: 40%
Compounded Profit Growth
10 Years: 24%
5 Years: 35%
3 Years: 42%
TTM: 65%
Stock Price CAGR
10 Years: %
5 Years: 75%
3 Years: 39%
1 Year: 90%
Return on Equity
10 Years: 23%
5 Years: 24%
3 Years: 25%
Last Year: 27%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 1 1 1 1 1 9 9 9 10 12 13 13
Reserves 7 11 12 13 15 20 25 33 40 50 76 109
2 0 0 0 0 2 1 2 0 0 34 36
2 2 2 2 5 5 7 8 10 15 21 12
Total Liabilities 12 15 15 16 21 36 41 52 61 77 144 171
4 4 4 4 4 6 14 16 19 27 36 81
CWIP 0 0 0 0 0 0 0 0 2 3 42 17
Investments 0 0 0 0 0 4 4 7 3 0 0 5
8 10 11 11 17 25 23 29 37 47 66 69
Total Assets 12 15 15 16 21 36 41 52 61 77 144 171

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
1 5 -1 -2 2 -1 -5 4 3 13 17 30
0 -1 1 1 0 -3 -0 -3 -1 -12 -54 -33
-1 -0 -0 -0 -0 8 -0 -0 -1 -1 41 10
Net Cash Flow 0 3 -1 -0 2 4 -5 1 2 0 5 7

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 100 45 93 133 136 78 101 104 99 94 113 59
Inventory Days 186 126 132 130 103 102 125 56 206 132 138 159
Days Payable 47 23 43 32 90 43 75 39 101 92 111 52
Cash Conversion Cycle 239 149 183 232 149 137 151 120 205 134 141 166
Working Capital Days 187 96 160 202 172 156 149 115 159 133 129 123
ROCE % 25% 44% 16% 12% 26% 27% 27% 33% 28% 33% 25%

Shareholding Pattern

Numbers in percentages

Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
68.39% 69.12% 69.12% 69.12% 69.12% 68.27% 68.27% 69.34% 69.34% 69.33% 69.33% 69.33%
0.00% 0.00% 0.02% 0.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
31.61% 30.88% 30.86% 30.86% 30.88% 31.73% 31.72% 30.67% 30.66% 30.67% 30.66% 30.67%
No. of Shareholders 3,3974,8145,7415,7455,4655,8436,4726,7476,4077,3307,5187,049

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Concalls

  • May 2023
    Transcript
    Notes
    PPT
  • Mar 2021
    Transcript
    Notes
    PPT